Antimicrobial susceptibility testing before first-line treatment for Helicobacter pylori infection in patients with dual or triple antibiotic resistance

Table 1 Demographic, clinical characteristics, eradication rates per intention-to-treat, compliance and adverse events of patients in each therapeutics group

	Dual H. pylori - resistance			Triple H. pylori- resistance
	C + M	C + L	M + L	C + M + L
	OAL-10	OAM-10	OAC-10	OAR-10
	(43)	(12)	(13)	(12)
Gender (females)	70%	67%	69%	67%
Age (yr)
Mean	51.6	52.8	50	53.3
Median (range)	51 (18-76)	52 (24-76)	50 (31-75)	53 (42-77)
Indication
Dyspepsia	95%	83%	84%	75%
Ulcer	5%	17%	16%	25%
ITT eradication	42/43 (97.6%)	11/12 (91.6%)	12/13 (92.3%)	7/12 (58.3%)
Compliance	93%	93%	93%	94%
Adverse events	22%	25%	23%	17%

O: Omeprazole; A: Amoxicillin; L: Levofloxacin; M: Metronidazole; C: Clarithromycin; R: Rifabutin; H. pylori: Helicobacter pylori; ITT: Intention-to-treat.